Find the latest Gilead Sciences news related to customer service below. We do our best to screen the news provided here for relevance and accuracy, but the links to articles found here are from 3rd parties so occassionally less pertinent materials get published. Please feel free to contact us to report other relevant articles, or to let us know of any material that should be removed.
Gilead Sciences, Inc. (GILD - Free Report) and its newly acquired cell therapy subsidiary –Kite Pharma- announced that they have inked an agreement to acquire Cell Design Labs, Inc. for $567 million. Gilead will also acquire 12.2% of Cell Design shares ...
EMERYVILLE, Calif., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Cell Design Labs, Inc., a privately-held biotechnology company developing disruptive CAR-T and T cell receptor (TCR) therapies, announced today that Gilead Sciences (Nasdaq:GILD) has agreed to ...
In this photo taken July 9, 2015, a man cycles near the headquarters of Gilead Sciences in Foster City, Calif. A bipartisan investigation by U.S. senators finds that the makers of a breakthrough drug for hepatitis C infection put profits before ...
Does Gilead's Kite Acquisition Offer A New Buying Opportunity? Gilead Sciences caught an upgrade Thursday following its Kite Pharma buyout. (Kris Tripplaar/Sipa USA/Newscom) .... Something Went Wrong! Please contact Customer Service. CLOSE. Cloudera ...
Gilead Sciences, Inc. (NASDAQ:GILD)'s latest quote $83.51 $0.17 1.32% will find technical support in $82.58 a share and a breakdown below this region would be a significantly bearish signal for Gilead Sciences, Inc. traders. It has underperformed by ...
As an investor, I love Gilead Sciences, however the key is what entry price do I want to buy? The answer can be found in the stock chart. Once Gilead Sciences falls back to $76.50, it becomes a strong buy. There is a huge amount of technical support at ...
Gilead Sciences (GILD - Get Report) is up sharply Wednesday but investors should not be too surprised. We said in recent update , "GILD only turned positive in late June, so we are not far off the lows, with plenty of room on the upside. Aggressive ...
Gilead Sciences Inc., a biopharmaceutical company with 9,000 employees across six continents, is about to unveil a 23-acre campus in La Verne that's expected to employ as many as 500 workers. The initial focus of the campus at 1800 Wheeler Ave. will be ...
Gilead Sciences, Inc. (NASDAQ:GILD)'s latest quote $73.27 $0.07 -0.23% will find technical support in $72.83 a share and a breakdown below this region would be a significantly bearish signal for Gilead Sciences, Inc. traders. Any way you dice it, a dip ...
Gilead Sciences, Inc. (NASDAQ:GILD)'s latest quote $70.86 $-0.97 -1.47% will find technical support in $69.86 a share and a breakdown below this region would be a significantly bearish signal for Gilead Sciences, Inc. traders. Any way you dice it, a ...
Gilead Sciences, Inc. (NASDAQ:GILD)'s latest quote $71.92 $0.3 1.8% will find technical support in $71.14 a share and a breakdown below this region would be a significantly bearish signal for Gilead Sciences, Inc. traders. Any way you dice it, a dip ...
Gilead Science Inc. (GILD - Get Report) is extending Tuesday's high volume gain. This impressive move has driven the stock to fresh June highs as a major bottom begins to take shape. Gilead is leaving behind a very solid base and, like much of the ...
Gilead Sciences, Inc. (NASDAQ:GILD)'s latest quote $65.59 $-3.48 1.19% will find technical support in $64.41 a share and a breakdown below this region would be a significantly bearish signal for Gilead Sciences, Inc. traders. ... More notable recent ...
Gilead's first-quarter conference call delivered another opportunity for analysts to ask management, 'Who are you going to buy and when?' ByAdam Feuerstein. May 3, 2017 6:47 PM EDT. For awhile Tuesday night, it seemed as if Gilead Sciences' (GILD - Get ...
When John Milligan speaks, people listen -- especially if they're Gilead Sciences (NASDAQ: GILD) shareholders. The big biotech's CEO and its CFO Robin Washington sat down to field questions at the RBC Capital Markets 2017 Healthcare Conference in ...
The biotech's shares hit $67.75 in premarket trading and are now at $65.85 after Gilead reported poor fourth-quarter earnings and 2017 guidance after the market close on Tuesday. Gilead expects to see sales drop by 22% in fiscal year 2017. This is ...
Gilead's HIV foundation isn't crumbling but the rest of the house is in need of serious repair. ByAdam Feuerstein. Feb 7, 2017 4:20 PM EST. Gilead Sciences (GILD - Get Report) said Tuesday that total product sales will decline sharply in 2017, hurt by ...
Gilead Sciences Inc. GILD is scheduled to report fourth-quarter 2016 results on Feb 7, after the market closes. Last quarter, the company missed expectations by 1.46%. Gilead's track record is mixed, with the company beating estimates in two of the ...
Investors in Gilead Sciences Inc. (GILD - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the January 20, 2017 $175 Put had some of the highest implied volatility of all equity ...
Stay Connected. Feedback · About Us · Investor Relations · Advertise · Reprints · Customer Service · Employment · Privacy Policy · Terms of Use · Topic Archive · Video Sitemap · Data · Affiliate · Press Room · ©1996-2017 TheStreet, Inc. All rights ...
Gilead Sciences Inc. (NASDAQ:GILD) announced top-line results from two Phase 3 clinical trials (SIMPLIFY 1 and 2) evaluating momelotinib, an investigational inhibitor of Janus kinase (JAK) compared to ruxolitinib or best alternative therapy (BAT) in ...
Yesterday in the Late Breaking Abstract (LBA) Oral Session at the American Association of the Study of Liver Diseases (AASLD) Meeting in Boston, investigators presented the results of the phase II trial for Gilead's GS4997 (now known as selonsertib) in ...
The risk to Gilead Sciences' (GILD) HIV franchise from competitors' drug studies has been 'underappreciated,' says RBC Capital Markets. ByRachel Aldrich. Oct 3, 2016 1:24 PM EDT. Read as Single Page. NEW YORK (TheStreet) -- Shares of Gilead Sciences ...
Credit Suisse Upgrades Tesoro, Alon USA To Buy · Wedbush: Buy Synchrony, OneMain, and FirstCash · More Posts ... Customer Service. Customer Center · Contact Us; Live Help. Create an Account. Subscribe to Barron's · Magazine Subscribers: Activate ...
After surveying doctors on the preferred hepatitis-C treatments, Baird's Brian Skorney and Neena Bitritto-Garg contend that Gilead Sciences (GILD) is likely to maintain its dominance over AbbVie (ABBV), Merck (MRK) and Johnson & Johnson (JNJ) but in ...
23 Celebrities Say They're Leaving The USA Since Trump WonFrank151. Undo. LendingTree Mortgage Quotes · Not enough vets ... China UnionPay Deploys AltiGen Com's (ATGN) Software-Based call center · OPEI's "LOOK BEFORE YOU PUMP" Ethanol ...
It is no secret that investors love dividends and stock buybacks. In recent years, there has been a larger shift into companies buying back shares of common stock, even while they have grown their dividends. Standard & Poor's has now shown that the ...
Shares of biopharmaceutical company Gilead Sciences (GILD - Get Report) have been subject to much downward pressure after reporting disappointing first-quarter earnings late last month. But the selling is overdone and creates an opportunity for ...
Gilead Sciences, Inc. (GILD - Analyst Report) just released its first quarter fiscal 2016 earnings results, posting earnings of $2.98 per share and revenue of $7.8 billion. Currently, GILD has a Zacks Rank #2 (Buy), but it is subject to change ...
The drug Descovy, which is made by Gilead Sciences, was approved by the U.S. Food and Drug Administration (FDA) the company announced this week. The combination drug is a daily pill that uses two already approved drugs for the disease. The drug can ...
Gilead Sciences, Inc. (GILD - Analyst Report) is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them. They have a broad-based focus on developing and marketing drugs to ...
It's expected to be a blockbuster. The FDA on Monday approved the latest combo HIV combo therapy from Gilead Sciences GILD -1.33% : Descovy. Analysts expect the drug to become a blockbuster which will easily cross $1 billion (and potentially $2 billion ...
This morning Gilead announced acquisition of ACC inhibitor class from Nimbus. While this asset is early, it shows Gilead's continuous effort in this space and now they have 4 assets in development for NASH. Clinical data abstract from EASL 2016 shows ...
Gilead Sciences Inc (GILD - Analyst Report) just released their fourth quarter fiscal 2015 earnings results, posting earnings of $3.32 and revenue of $8.5 billion. Currently, GILD has a Zacks Rank #1 (Strong Buy), but it is subject to change following ...
In addition, investors are concerned on 2016 Gilead guidance – where we think total product sales guidance will encapsulate consensus HCV — but there's Street uncertainty given consensus Q4 seems OK but USA consensus could be $100-300M too high ...
GILD's Q4 Hep C scripts are tracking generally fine – towards ~$12.6B USA for 2015, slightly above our estimate of $12.5B. Q4 HCV USA scripts tracking towards $2.5B (-6% Q/Q), slightly above our estimate of $2.4B. Specifically, Q4 Harvoni USA scripts ...
For the week ending September 18, which followed the Labor Day week, scripts for Gilead's Harvoni totaled 7,451, up +13% w/w. New Rx were 2,778, up +22% w/w. This implies a total franchise TRx (i.e. Sovaldi + Harvoni) of 9,135, up +13% w/w, and ...
Based on our APP for USA sales, we're below cons and we believe cons USA needs to come down for 2015. Management believes end-user demand is much stronger based on scripts “written” rather than scripts filled, and they believe payor restrictions ...
Based on our APP for USA sales, we're below cons and we believe cons USA needs to come down for the year. That said, management believes end-user demand is much stronger based on scripts “written” rather than scripts filled, and they believe payor ...
This is consistent with flattening scripts and decelerating sales that we've seen – our APP predicts Gilead Hep C sales of $11.6B USA and lower than consensus of $12.4B USA for 2015. While Gilead mgmt has stated that they still see strong USA demand ...
And if you believe they have diagnosed all the cases of Hep-c in the USA or otherwise, you would have to be an analyst or a shorty . JULY 27, 2015 8:59 P.M.; new liver here wrote: The cost of a liver transplant is much more than 6-8 times the cost of ...
With small inventory adjustments included, that implies $11.7B USA total for Harvoni +Sovaldi. *Contact us for our Harvoni-Viekira APP* • At our 2015 Doctor Days, our HCV KOLs reiterated potential for at least 2x pts treated in 2015 over 2014 and ...
Gilead Sciences Inc (GILD - Free Report) is a research-based biopharmaceutical company that discovers, develops, and commercializes therapeutic treatments. Its portfolio of products and pipeline of untried drugs include treatments for HIV/AIDs, liver ...
Gilead Sciences, Inc. (GILD - Analyst Report) may be a solid choice for technical investors, as the firm saw some good news with its moving average crossover. GILD just saw its 50 Day Moving Average break out above its 200 Day Simple Moving Average, ...
Gilead's weekly Hep C scripts are tracking towards $3.1-3.2B USA (vs cons $3.1B USA) for Q2:15, and $12B USA (in line with consensus ~ $12B USA) for 2015. …we estimate 2015 sales of $10.5B for Harvoni based on 75-80% capture rate and 40-46% ...
With small inventory adjustments included, that implies $12B USA total for Harvoni+Sovaldi. At our 2015 Boston Doctor Day, our HCV panel reaffirmed that there is potential for at least 2x pts treated in 2015 over 2014 and minimal concern for decline in ...
NEW YORK (TheStreet) -- Shares of Gilead Sciences (GILD - Get Report) are lower by 0.81% to $104.35 in midday trading on Wednesday. Yesterday, Bernstein analyst Geoff Porges said the pharmaceutical company should acquire Vertex Pharmaceuticals (VRTX ...
Over the course of this long bull market, biotech stocks have been very, very good for their owners. Perhaps too good. Investors have shown such rabid enthusiasm for biotechs—especially small, unproven companies that have yet to bring a drug to ...
Gilead, without a doubt, has proven itself to be a leader in the biotechnology industry. The stock has had an extremely bullish pattern over the last four years, growing over 400% in stock price since March 2011. However, over the last 6 months, the ...
BMC STOCK H, STCK, 18.16, +3.48%. MURPHY USA, MUSA, 65.60, +3.08%. INSPERITY I, NSP, 70.76, +2.21%. COMMERCIAL, CVGI, 3.03, +2.02%. BRASKEM S A, BAK ... Client Support. Contact Us · Share Feedback · Media · Careers · Affiliate · Advertise ...
